Breaking News, Trials & Filings

Abbvie’s RINVOQ Wins EC Approval

For patients with rheumatoid arthritis who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

AbbVie received approval from the European Commission for RINVOQ (upadacitinib) for the treatment of adult patients with moderate to severe active rheumatoid arthritis who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). RINVOQ is a once-daily selective and reversible JAK inhibitor and may be used as monotherapy or in combination with methotrexate (MTX). “We are proud to offer this once-daily tablet as a new treatment ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters